Project Grant R01CA308198
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $633K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Cancer Institute awarded The University of Texas Southwestern Medical Center $501,803 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to decode the stromal niches of antigen-presenting cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. The research aims to elucidate interactions between antigen-presenting cancer-associated fibroblasts (APCAFs) and other cell types within specialized stromal niches in pancreatic tumors. The work will examine...
- The National Cancer Institute awarded the University of Texas MD Anderson Cancer Center $645,865 on July 1, 2026, under Cancer Biology Research (CFDA 93.396) to investigate how perineural invasion in cutaneous squamous cell carcinoma drives immunotherapy resistance through neuroimmune mechanisms. The research addresses the molecular pathway linking nerve invasion to tumor immune suppression. The project will investigate how activating transcription factor 3 (ATF3)-dependent transcriptional...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded $402,011 to The University of Texas Southwestern Medical Center on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate how the KEAP1-NRF2 redox-sensing pathway regulates CD8 T-cell adaptation to persistent antigen receptor signaling in cancer and chronic infection contexts. The funded research addresses T-cell exhaustion, a dysfunctional...
- The National Cancer Institute awarded MD Anderson Cancer Center $669,540 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to elucidate the roles of the CD24 ligand in early lung cancer development, immune evasion, and response to KRAS-targeted therapy. The research investigates CD24 signaling in KRAS-mutant lung adenocarcinomas (KM-LUADs), which account for approximately 30 percent of lung adenocarcinomas in lifetime smokers. Preliminary findings indicate CD24 elevation...
- The National Cancer Institute awarded The University of Texas Southwestern Medical Center $404,922 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to support research targeting a novel ferroptosis defense pathway in pancreatic cancer. The funded research investigates cytochrome C (CYCS) as a suppressor of ferroptosis—an iron-dependent form of cell death driven by lipid peroxidation—in pancreatic ductal adenocarcinoma. The work builds on genome-wide CRISPR screen...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $374,006 on June 9, 2026, under the Cancer Biology Research program (CFDA 93.396) to support research delineating the role of TREM2 in chronic pancreatitis. The recipient will conduct integrative single-cell transcriptomics, spatially resolved imaging, and transgenic mouse model studies to investigate how loss of TREM2 expression in macrophages disrupts immune homeostasis and drives chronic pancreatitis...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $586,101 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) in the bone tumor microenvironment of prostate cancer bone metastasis. The research addresses immune checkpoint therapy resistance in bone metastatic prostate cancer by characterizing how the bone tumor microenvironment conditions PMN-MDSCs to...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $621,632 on June 17, 2026, under the Cancer Treatment Research program (CFDA 93.395) to elucidate the molecular and metabolic mechanisms underlying disulfidptosis and therapeutically target this form of regulated cell death in SLC7A11-high cancers. The research employs human cancer cell lines and integrated cell-based molecular analyses including metabolomics, proteomics, CRISPR screening, and biochemical...
- The Defense Health Agency awarded The University of Texas MD Anderson Cancer Center $1,399,964 on September 16, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support accelerating translational therapeutics from target discovery to clinical application for pancreatic cancer and beyond. Work is performed in Houston, Texas, with a period of performance through September 14, 2029. The award funds a project grant supporting MD Anderson's translational oncology...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $141,195 on May 15, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support a K99/R00 career development award focused on deciphering how tumor suppressor gene deficiencies modulate pancreatic ductal adenocarcinoma (PDAC) response to oncogenic KRAS inhibition and immunotherapy. During the K99 mentored phase, the recipient will use isogenic patient-derived organoid and xenograft models to...